Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.

Read it at Medical Xpress ↗

← Front page